As of today (2023-03-29), Biogen's current share price is ARS8135.00. Biogen's E10 for the quarter that ended in Dec. 2022 was ARS522.99. Biogen's Shiller PE Ratio for today is 15.55.
The historical rank and industry rank for Biogen's Shiller PE Ratio or its related term are showing as below:
BUE:BIIB'
s Shiller PE Ratio Range Over the Past 10 Years
Min: 9.8 Med: 33.27 Max: 110.75
Current: 13.36
During the past years, Biogen's highest Shiller PE Ratio was 110.75. The lowest was 9.80. And the median was 33.27.
BUE:BIIB's Shiller PE Ratio is ranked better than 75.42% of 472
companies
in the Drug Manufacturers industry
Industry Median: 23.61
vs BUE:BIIB: 13.36
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
Biogen's adjusted earnings per share data for the three months ended in Dec. 2022 was ARS635.393. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is ARS522.99 for the trailing ten years ended in Dec. 2022.
Shiller PE for Stocks: The True Measure of Stock Valuation
Biogen Shiller PE Ratio Historical Data
The historical data trend for Biogen's Shiller PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Biogen Annual Data
Trend
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Shiller PE Ratio
27.45
21.24
15.16
13.53
13.69
Biogen Quarterly Data
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Shiller PE Ratio
13.53
11.49
10.51
13.34
13.69
Competitive Comparison
For the Drug Manufacturers - General subindustry, Biogen's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biogen Shiller PE Ratio Distribution
For the Drug Manufacturers industry and Healthcare sector, Biogen's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Biogen's Shiller PE Ratio falls in comparison to its industry or sector. The grey bar indicates the Shiller PE Ratio's extreme value range as defined by GuruFocus.
Biogen Shiller PE Ratio Calculation
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
Biogen's Shiller PE Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biogen's E10 for the quarter that ended in Dec. 2022 is calculated as:
For example, Biogen's adjusted earnings per share data for the three months ended in Dec. 2022 was:
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Biogen (BUE:BIIB) Shiller PE Ratio Explanation
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Be Aware
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Biogen Shiller PE Ratio Related Terms
Thank you for viewing the detailed overview of Biogen's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.
Create New Portfolio
Portfolio Contest
Personalize
Premium Gurus 
(0.3%) Volume: 6 Mar. 28
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
BUE:BIIB has been successfully added to your 
